

Meet the Management Series – Generics

London, 10 August 2021 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the third event in its 2021 'Meet the Management' series for investors and analysts, to be held on:

Thursday 23 September, 14:00-15:30 British Summer Time.

This event will cover the Generics business and will be hosted by Hikma's CEO, Siggi Olafsson, and President of Generics, Brian Hoffmann.

The speakers for the Generics event will be:

Siggi Olafsson, CEO Brian Hoffmann, President, Generics Kristy Ronco, Chief Commercial Officer, Generics Mike Balog, SVP, Generics Operations

The event will be broadcast as a webinar with a live Q&A. A replay will be available after the event.

Please register your attendance in advance by clicking here.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal +44 (0)20 7399 2760/ +44 7776 477050 EVP, Strategic Planning and Global Affairs

Guy Featherstone +44 (0)20 3892 4389/ +44 7795 896738 Senior Investor Relations Manager

Layan Kalisse +44 (0)20 7399 2788/ +44 7970 709912 Investor Relations Analyst

uk-investors@hikma.uk.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com